First-Line Therapy for Rosacea
The first-line treatment for rosacea is topical therapy with azelaic acid 15% gel/foam, ivermectin 1% cream, or metronidazole (0.75% or 1.0% formulations) based on the specific phenotype presentation. 1, 2
Treatment Algorithm Based on Phenotype
For mild to moderate inflammatory lesions (papulopustular rosacea):
- Topical azelaic acid 15% gel/foam, ivermectin 1% cream, or metronidazole (0.75% or 1.0%) are recommended first-line options 1, 2
- Azelaic acid produces significant reduction in inflammatory lesions and perilesional erythema 1
- Ivermectin 1% cream works by reducing Demodex folliculorum density and downregulating inflammatory markers 1
- Metronidazole can produce up to 65% decrease in inflammatory lesion counts 1
For moderate rosacea requiring more rapid control:
For severe inflammatory lesions:
For persistent erythema:
Newer Treatment Options
- Encapsulated benzoyl peroxide 5% (E-BPO 5%) shows rapid improvement by week 2 with progressive clinical improvement for up to 52 weeks 1, 2
- Minocycline foam 1.5% is FDA-approved for moderate to severe inflammatory rosacea 1, 2
Application and Usage Guidelines
- Ivermectin 1% cream should be applied once daily 1
- When using both azelaic acid 15% gel and ivermectin 1% cream, apply one in the morning and one in the evening to minimize potential irritation 1
- Assess improvement in inflammatory lesion counts and erythema after 4-6 weeks of treatment 1
Important Clinical Considerations
- Treatment should be tailored to the specific signs and symptoms that are most troubling to the patient 1
- General skincare measures are essential adjuncts to pharmacological treatment:
Special Considerations for Ocular Rosacea
- Lid hygiene is recommended for mild cases of ocular rosacea 2
- Oral doxycycline is recommended for moderate to severe ocular rosacea 2
- Referral to an ophthalmologist may be necessary for patients with significant ocular complications 4
Common Pitfalls to Avoid
- Neglecting maintenance therapy: Up to two-thirds of patients may relapse when therapy is discontinued 1, 2
- Poor adherence due to skin irritation: Up to 89% of patients may discontinue therapy within a month 1
- Overlooking combination therapy for moderate and severe presentations 1, 2
- Not addressing all phenotypic features of rosacea simultaneously 1, 2
- Failing to consider potential triggers such as Helicobacter pylori infection or Demodex folliculorum infestation in resistant cases 5